Patients in remission at time of LMP-T infusion
| Patient . | Institution/ID . | Age/sex . | Diagnosis . | Days post-HSCT . | B or T cell . | Type of T cell/donor . | Total cell dose . | Response at 8 weeks postinfusion . | Outcome (length of follow-up) . | GVHD . | Toxicity possibly attributed to LMP-Ts . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BCM/1145 | 26/M | HL (LMP1+) | 636* | B | LMP2, MRD | 4 × 107/m2 | Relapse | Died of disease (2 mo) | None | None |
| 2 | BCM/1186 | 51/M | DLBCL (EBER+, LMP1+) | 77 | B | LMP2, MUD | 4 × 107/m2 | Remains in remission | Died of HSCT complications (6 mo) | Reactivation; chronic | None |
| 3 | BCM/1242 | 58/M | HL/CLL (EBER+, LMP1+) | 1825* | B | LMP2, MRD | 4 × 107/m2 | Remains in remission | Died of CLL progression (3 y) | None | None |
| 4 | BCM/1285 | 60/F | HL/CLL (LMP1+) | 167 | B | LMP2, MRD | 4 × 107/m2 | Remains in remission | Remains in remission (3+ years) | Chronic | None |
| 5 | BCM/1313 | 44/M | NKTCL (EBER+) | 119 | T | LMP1/2, MRD | 4 × 107/m2 | Remains in remission | Remains in remission (3+ years) | Chronic | None |
| 6 | BCM/1933 | 10/F | CAEBV/HLH (EBV‐ PCR+) | 120 | T | LMP1/2, MUD | 4 × 107/m2 | Remains in remission | Remains in remission† (3+ years) | None | None |
| 7 | BCM/1640 | 13/M | EBV+ LPD (EBER+) | 183 | T | LMP1/2, MRD | 4 × 107/m2 | Remains in remission | Remains in remission (3+ years) | None | None |
| 8 | BCM/1943 | 34/F | HL (EBER+) | 207 | B | LMP1/2, MRD | 1.2 × 108/m2 | Remains in remission | Remains in remission (3+ years) | Reactivation; chronic | None |
| 9 | BCM/2393 | 31/M | NKTCL (EBER+) | 122 | T | LMP1/2, MRD | 1.2 × 108/m2 | Relapse | Died of disease (8 mo) | None | None |
| 10 | BCM/2562 | 17/M | DLBCL (EBER+) | 149 | B | LMP1/2, MUD | 3 × 108/m2 | Remains in remission | Died of disease (3+ years) | Reactivation | None |
| 11 | BCM/2812 | 51/M | DLBCL/CLL (EBER+) | 329 | B | LMP1/2, MRD | 3 × 108/m2 | Remains in remission | Remains in remission (3+ years) | None | None |
| 12 | BCM/2705 | 6/F | HL (EBER+, LMP1+) | 265 | B | LMP1/2, MRD | 3 × 108/m2 | Remains in remission | Remains in remission (3+ years) | None | None |
| 13 | BCM/2879 | 20/F | CAEBV/HLH (EBV‐ PCR+) | 175 | T | LMP1/2, MUD | 3 × 108/m2 | Remains in remission | Remains in remission (3+ years) | None | None |
| 14 | BCM/2997 | 17/F | EBV+ LPD/LYG (EBER+, LMP1+) | 108 | B | LMP1/2, MUD | 4 × 107/m2 (fixed) | Remains in remission | Remains in remission (3+ years) | None | None |
| 15 | BCM/3299 | 12/M | NKTCL (EBER+) | 122 | T | LMP1/2, MRD | 2 × 107/m2 (fixed) | Relapsed | Died of disease (6 wk) | None | None |
| 16 | CNMC/P0148 | 16/M | NKTCL (EBER+) | 42 | T | LMP1/2, MMRD | 2 × 107/m2 | Remains in remission | Remains in remission (13 mo) | None | None |
| 17 | CNMC/P0175 | 22/M | CAEBV (EBV‐PCR+) | 76 | T | LMP1/2, MMRD | 2 × 107/m2 | Relapsed/new NKTCL | Alive with disease (6 mo) | None | None |
| 18 | CNMC/P0182 | 19/M | CAEBV/HLH (EBV‐PCR+) | 84 | T | LMP1/2, MRD | 2 × 107/m2 | Remains in remission | Remains in remission (6 mo) | None | None |
| 19 | CNMC/P0129 | 12/F | NKTCL (EBER+) | 42 | T | LMP1/2, MMRD | 4 × 107/m2 | Remains in remission | Relapsed‡ (15 mo) | None | None |
| Patient . | Institution/ID . | Age/sex . | Diagnosis . | Days post-HSCT . | B or T cell . | Type of T cell/donor . | Total cell dose . | Response at 8 weeks postinfusion . | Outcome (length of follow-up) . | GVHD . | Toxicity possibly attributed to LMP-Ts . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BCM/1145 | 26/M | HL (LMP1+) | 636* | B | LMP2, MRD | 4 × 107/m2 | Relapse | Died of disease (2 mo) | None | None |
| 2 | BCM/1186 | 51/M | DLBCL (EBER+, LMP1+) | 77 | B | LMP2, MUD | 4 × 107/m2 | Remains in remission | Died of HSCT complications (6 mo) | Reactivation; chronic | None |
| 3 | BCM/1242 | 58/M | HL/CLL (EBER+, LMP1+) | 1825* | B | LMP2, MRD | 4 × 107/m2 | Remains in remission | Died of CLL progression (3 y) | None | None |
| 4 | BCM/1285 | 60/F | HL/CLL (LMP1+) | 167 | B | LMP2, MRD | 4 × 107/m2 | Remains in remission | Remains in remission (3+ years) | Chronic | None |
| 5 | BCM/1313 | 44/M | NKTCL (EBER+) | 119 | T | LMP1/2, MRD | 4 × 107/m2 | Remains in remission | Remains in remission (3+ years) | Chronic | None |
| 6 | BCM/1933 | 10/F | CAEBV/HLH (EBV‐ PCR+) | 120 | T | LMP1/2, MUD | 4 × 107/m2 | Remains in remission | Remains in remission† (3+ years) | None | None |
| 7 | BCM/1640 | 13/M | EBV+ LPD (EBER+) | 183 | T | LMP1/2, MRD | 4 × 107/m2 | Remains in remission | Remains in remission (3+ years) | None | None |
| 8 | BCM/1943 | 34/F | HL (EBER+) | 207 | B | LMP1/2, MRD | 1.2 × 108/m2 | Remains in remission | Remains in remission (3+ years) | Reactivation; chronic | None |
| 9 | BCM/2393 | 31/M | NKTCL (EBER+) | 122 | T | LMP1/2, MRD | 1.2 × 108/m2 | Relapse | Died of disease (8 mo) | None | None |
| 10 | BCM/2562 | 17/M | DLBCL (EBER+) | 149 | B | LMP1/2, MUD | 3 × 108/m2 | Remains in remission | Died of disease (3+ years) | Reactivation | None |
| 11 | BCM/2812 | 51/M | DLBCL/CLL (EBER+) | 329 | B | LMP1/2, MRD | 3 × 108/m2 | Remains in remission | Remains in remission (3+ years) | None | None |
| 12 | BCM/2705 | 6/F | HL (EBER+, LMP1+) | 265 | B | LMP1/2, MRD | 3 × 108/m2 | Remains in remission | Remains in remission (3+ years) | None | None |
| 13 | BCM/2879 | 20/F | CAEBV/HLH (EBV‐ PCR+) | 175 | T | LMP1/2, MUD | 3 × 108/m2 | Remains in remission | Remains in remission (3+ years) | None | None |
| 14 | BCM/2997 | 17/F | EBV+ LPD/LYG (EBER+, LMP1+) | 108 | B | LMP1/2, MUD | 4 × 107/m2 (fixed) | Remains in remission | Remains in remission (3+ years) | None | None |
| 15 | BCM/3299 | 12/M | NKTCL (EBER+) | 122 | T | LMP1/2, MRD | 2 × 107/m2 (fixed) | Relapsed | Died of disease (6 wk) | None | None |
| 16 | CNMC/P0148 | 16/M | NKTCL (EBER+) | 42 | T | LMP1/2, MMRD | 2 × 107/m2 | Remains in remission | Remains in remission (13 mo) | None | None |
| 17 | CNMC/P0175 | 22/M | CAEBV (EBV‐PCR+) | 76 | T | LMP1/2, MMRD | 2 × 107/m2 | Relapsed/new NKTCL | Alive with disease (6 mo) | None | None |
| 18 | CNMC/P0182 | 19/M | CAEBV/HLH (EBV‐PCR+) | 84 | T | LMP1/2, MRD | 2 × 107/m2 | Remains in remission | Remains in remission (6 mo) | None | None |
| 19 | CNMC/P0129 | 12/F | NKTCL (EBER+) | 42 | T | LMP1/2, MMRD | 4 × 107/m2 | Remains in remission | Relapsed‡ (15 mo) | None | None |
BCM, Baylor College of Medicine; CLL, chronic lymphocytic leukemia; CNMC, Children’s National Medical Center; DLBCL, diffuse large B-cell lymphoma; HLH, hemophagocytic lymphohistiocytosis; LYG, lymphomatoid granulomatosis; MMRD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; PCR, polymerase chain reaction.
Patients had relapsed post-HSCT and attained remission with chemotherapy and/or DLI before receiving LMP-Ts.
Developed a second malignancy (Ewing’s sarcoma) but remains alive and disease free >5 y from LMP-T infusion.
Patient’s donor subsequently diagnosed with NKTCL ∼12 mo after LMP-T infusion.